Tag Archives: Ram Selvaraju

Regulus (RGLS) Has a New Rating from H.C. Wainwright

Regulus (RGLS – Research Report) received a Buy rating and a $2 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed last Monday at $0.60, close to its 52-week low of $0.50. Selvaraju commented: “We have

Analysts Offer Insights on Healthcare Companies: ObsEva SA (NASDAQ: OBSV) and Alimera (NASDAQ: ALIM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ObsEva SA (OBSV – Research Report) and Alimera (ALIM – Research Report) with bullish sentiments. ObsEva SA (OBSV) H.C. Wainwright analyst Ram

Arcadia Biosciences (RKDA) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Arcadia Biosciences (RKDA – Research Report) today and set a price target of $14. The company’s shares closed last Monday at $7.63. According to TipRanks.com, Selvaraju ‘s ranking currently consits

H.C. Wainwright Sticks to Their Buy Rating for Microbot Medical Inc (MBOT)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Microbot Medical Inc (MBOT – Research Report) today and set a price target of $10. The company’s shares closed last Monday at $5.42. Selvaraju observed: “Our price target is derived

Analysts Offer Insights on Healthcare Companies: Nucana Plc (NASDAQ: NCNA), Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) and Trillium Therapeutics (NASDAQ: TRIL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nucana Plc (NCNA – Research Report), Entasis Therapeutics Holdings Inc (ETTX – Research Report) and Trillium Therapeutics (TRIL – Research Report). Nucana Plc (NCNA) H.C.

Urovant Sciences Ltd (UROV) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Urovant Sciences Ltd (UROV – Research Report), with a price target of $28. The company’s shares closed last Monday at $7.54. Selvaraju commented: “We have